TYK MEDICINES-B (02410) Enters Potential General Agency Agreement with Sichuan Huiyu for TY-9591

Stock News

Aug 26, 2025

TYK MEDICINES-B (02410) announced that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published an announcement on August 26, 2025, regarding its board of directors' approval for Sichuan Huichenxin Pharmaceutical Co., Ltd. (Sichuan Huichenxin), a wholly-owned subsidiary of Sichuan Huiyu, to enter into a potential general agency agreement with the Company for TY-9591, the Company's core product.

Under the potential general agency arrangement, the Company may agree to appoint Sichuan Huichenxin as the exclusive general agent for TY-9591 in China (excluding Hong Kong, Macau, Taiwan, and any other overseas regions), with initial milestone payments of up to RMB 150 million.

As the Group is about to enter the commercialization phase of TY-9591, if the potential general agency arrangement is implemented, the Group will be able to leverage the extensive existing sales and agency networks of Sichuan Huichenxin and Sichuan Huiyu. Sichuan Huiyu is an established pharmaceutical enterprise with a complete industrial chain and extensive experience in pharmaceutical agency and sales in China.

Therefore, the Company believes that this arrangement will help enhance the sales and revenue of TY-9591, accelerate market penetration, reduce the Group's costs in establishing new sales channels, and strengthen the Group's brand image through collaboration with a renowned pharmaceutical company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1187428385"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187428385\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187428385?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187428385","market":"sh","top_or_hot":-1,"title":"TYK MEDICINES-B (02410) Enters Potential General Agency Agreement with Sichuan Huiyu for TY-9591","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) announced that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published an announcement on August 26, 2025, regarding its board of directors' approval for Sichuan Huichenxin Pharmaceutical Co., Ltd. (Sichuan Huichenxin), a wholly-owned subsidiary of Sichuan Huiyu, to enter into a potential general agency agreement with the Company for TY-9591, the Company's core product.</p>\n<p>Under the potential general agency arrangement, the Company may agree to appoint Sichuan Huichenxin as the exclusive general agent for TY-9591 in China (excluding Hong Kong, Macau, Taiwan, and any other overseas regions), with initial milestone payments of up to RMB 150 million.</p>\n<p>As the Group is about to enter the commercialization phase of TY-9591, if the potential general agency arrangement is implemented, the Group will be able to leverage the extensive existing sales and agency networks of Sichuan Huichenxin and Sichuan Huiyu. Sichuan Huiyu is an established pharmaceutical enterprise with a complete industrial chain and extensive experience in pharmaceutical agency and sales in China.</p>\n<p>Therefore, the Company believes that this arrangement will help enhance the sales and revenue of TY-9591, accelerate market penetration, reduce the Group's costs in establishing new sales channels, and strengthen the Group's brand image through collaboration with a renowned pharmaceutical company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B (02410) Enters Potential General Agency Agreement with Sichuan Huiyu for TY-9591</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B (02410) Enters Potential General Agency Agreement with Sichuan Huiyu for TY-9591\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-26 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) announced that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published an announcement on August 26, 2025, regarding its board of directors' approval for Sichuan Huichenxin Pharmaceutical Co., Ltd. (Sichuan Huichenxin), a wholly-owned subsidiary of Sichuan Huiyu, to enter into a potential general agency agreement with the Company for TY-9591, the Company's core product.</p>\n<p>Under the potential general agency arrangement, the Company may agree to appoint Sichuan Huichenxin as the exclusive general agent for TY-9591 in China (excluding Hong Kong, Macau, Taiwan, and any other overseas regions), with initial milestone payments of up to RMB 150 million.</p>\n<p>As the Group is about to enter the commercialization phase of TY-9591, if the potential general agency arrangement is implemented, the Group will be able to leverage the extensive existing sales and agency networks of Sichuan Huichenxin and Sichuan Huiyu. Sichuan Huiyu is an established pharmaceutical enterprise with a complete industrial chain and extensive experience in pharmaceutical agency and sales in China.</p>\n<p>Therefore, the Company believes that this arrangement will help enhance the sales and revenue of TY-9591, accelerate market penetration, reduce the Group's costs in establishing new sales channels, and strengthen the Group's brand image through collaboration with a renowned pharmaceutical company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1187428385","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187428385","pubTimestamp":1756212022,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) announced that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published an announcement on August 26, 2025, regarding its board of directors' approval for Sichuan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1574":"生物医药B类股","TY":"Tri-Continental Corp","02410":"同源康医药-B"},"translate_title":"TYK MEDICINES-B(02410)与四川汇宇就TY-9591订立潜在总代理协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"TY":1,"09939":1,"02410":1},"content_text":"TYK MEDICINES-B (02410) announced that Sichuan Huiyu Pharmaceutical Co., Ltd. (Sichuan Huiyu) published an announcement on August 26, 2025, regarding its board of directors' approval for Sichuan Huichenxin Pharmaceutical Co., Ltd. (Sichuan Huichenxin), a wholly-owned subsidiary of Sichuan Huiyu, to enter into a potential general agency agreement with the Company for TY-9591, the Company's core product.\nUnder the potential general agency arrangement, the Company may agree to appoint Sichuan Huichenxin as the exclusive general agent for TY-9591 in China (excluding Hong Kong, Macau, Taiwan, and any other overseas regions), with initial milestone payments of up to RMB 150 million.\nAs the Group is about to enter the commercialization phase of TY-9591, if the potential general agency arrangement is implemented, the Group will be able to leverage the extensive existing sales and agency networks of Sichuan Huichenxin and Sichuan Huiyu. Sichuan Huiyu is an established pharmaceutical enterprise with a complete industrial chain and extensive experience in pharmaceutical agency and sales in China.\nTherefore, the Company believes that this arrangement will help enhance the sales and revenue of TY-9591, accelerate market penetration, reduce the Group's costs in establishing new sales channels, and strengthen the Group's brand image through collaboration with a renowned pharmaceutical company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}